Biotech company Oxeia Biopharmaceuticals has announced its first crowdfunding campaign was oversubscribed, raising over $1.2 million before its scheduled close. The company, which develops concussion therapeutics, has surpassed its crowdfunding goal, reflecting interest in its clinical-stage ghrelin therapy for persistent concussion symptoms. The therapy, OXE103, demonstrated an 85%… Read More
The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, an innovative therapy showed encouraging results in tackling melanoma. Elsewhere, why is… Read More
News round-up for 19 – 23 January by Bruno Quinney, Content Team at DDW. This week in DDW, innovative therapies have shown encouraging results in tackling melanoma and concussion. Elsewhere, a UK-Canadian partnership looks to advance vaccine technology. The top stories: Combination therapy could slash melanoma mortality… Read More
Biotech Oxeia Biopharmaceuticals is advancing a potential first FDA-approved concussion treatment into Phase IIb clinical testing. OXE103, a therapy for persistent concussion symptoms, demonstrated an 85% responder rate in Phase IIa clinical testing and will be evaluated in Phase IIb trial. Between 1.4 and 4.2 million people… Read More
In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business. In this episode, Megan Thomas is in conversation with CEO of… Read More
Oxeia Biopharmaceuticals, a clinical stage biotech company developing a drug treatment for concussion to address underlying neuro-metabolic dysfunction and axonal injury, has announced “game-changing” results of a Phase IIa pilot study of OXE103 at the University of Kansas Medical Center (KUMC). The study results suggest a potentially… Read More
